Ruth Coleman

Picture of Ruth Coleman

Position:Senior Research Statistician

Telephone:01865 857253


Ruth is a Senior Research Statistician at the Diabetes Trials Unit.

Her ongoing projects include the expansion of the UKPDS Risk Engine to include estimates of both cardiovascular and microvascular disease risk, and modelling life expectancy in type 2 diabetes.

She is currently the statistical lead for the ACE study.

Latest publications

Can the Cardiovascular Risk Reductions Observed with Empagliflozin in the EMPA-REG OUTCOME Trial be Explained by the Changes Seen in Conventional Cardiovascular Risk Factor Levels?
Ruth L. Coleman et al.
Diabetes Obes Metab. 2020

Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86)
Ernesto Maddaloni et al.
Lancet Diabetes Endocrinol 2020;8:206-15

Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes
Ruth L. Coleman et al.
Cardiovasc Diabetol 2019;18:135

Long-term Risk of Cardiovascular Disease in Individuals with Latent Autoimmune Diabetes of Adults (UKPDS 85)
E. Maddaloni et al.
Diabetes Obese Metab. 2019;2019:2115-2122

Simulating the impact of targeting lower systolic blood pressure and LDL-cholesterol levels on type 2 diabetes complication rates
Mostafa SA et al.
J Diabetes Complications 2019;33:69-74

Conference abstract
Comparison of medical resources, costs, and health utilities among patients with CHD and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation Trial (ACE)
L. Mc Morrow et al.
Diabetelogia 2018;61:S344